Evaluation of the efficacy of a live Escherichia coli biotherapeutic product (asymptomatic bacteriuria E. coli 212).

Gilad Segev Hilla Chen Jonathan D DearBeatriz Martínez LópezJully PiresDavid J KlumppAnthony J SchaefferJodi L Westropp

Published in: Journal of veterinary internal medicine (2024)

These data suggest that intravesicular administration of ASB E. coli 212 is not inferior to antimicrobials for the treatment of recurrent UTI in dogs. This biotherapeutic agent could help alleviate the need for antimicrobials for some dogs with recurrent UTI, improving antimicrobial stewardship.

Keyphrases

escherichia coli
urinary tract infection
biofilm formation
machine learning
combination therapy
cystic fibrosis
pseudomonas aeruginosa
deep learning
smoking cessation